A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin cancer after five years, new data confirming its prolonged benefit show.
Patients with severe melanoma who got the injection — along with Merck’s cancer drug Keytruda — were 49% less likely to die or have their cancer return than those who received only Keytruda, the companies said Tuesday.
While the five-year data is similar to three-year datapreviously disclosed by the companies, it stands to be a cancer treatment milestone due to the risk of late-stage melanoma returning after surgery. Showing ...
